Peak Pharmaceutical has another postdoctoral entrance to open the topic.
Release time:
2023-06-25
On the afternoon of June 15, the post-doctoral research station of Jianfeng Pharmaceutical held a review meeting for Dr. Wu Zhuo from Donghua University.
Dr. Wu Zhuo's main research directions are research and development of new cardiovascular and cerebrovascular drugs, total synthesis of natural products, and organic synthesis technology. He has published more than ten papers in internationally renowned academic journals such as Eur. J. Med. Chem, and has won many excellent papers awards at the annual meeting of microbiology and biochemical drugs of Shanghai Pharmaceutical Association. Dr. Wu Zhuo's research project in the post-doctoral research station of Jianfeng Pharmaceutical is entitled "Design, synthesis and anti-tumor mechanism of oxindole compounds based on p53 target". At the opening review meeting, he elaborated on the background of the research project, the significance of the topic, the key problems to be solved, the solution plan, the main technical difficulties and innovation points, the work schedule and the budget, and accepted the questions and comments of the expert group.
The expert group of the opening review meeting is headed by Professor Chen Zhilong of Donghua University. Its members include Professor Wu Fanhong of Shanghai University of Applied Technology, Professor Fang Weijie of Zhejiang University's School of Pharmacy, Professor Jin Zhunian of Jinhua Vocational and Technical College of Pharmacy and Dr. Zhang Qiang, chief scientist of Jianfeng Pharmaceutical. Among them, Professor Chen Zhilong and Dr. Zhang Qiang will serve as Dr. Wu Zhuo's on-site co-site mentors respectively. Leaders of Jinhua Human Resources and Social Security Bureau, Science and Technology Bureau, Jinhua Development Zone Organization Human Resources and Social Security Bureau and other relevant departments, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, also attended the meeting. Jiang Xiaomeng, the host of the
opening review meeting, expressed his heartfelt thanks to all the leading experts for their arrival, and briefly introduced the development process of Jianfeng Pharmaceutical, and affirmed the work achievements of the postdoctoral workstation that has been rated as an excellent workstation for many years. He believes that Dr. Wu Zhuo's inbound research project has scientific significance and application value, and expects the research project to achieve the desired results. Huang Jinlong said that the P53 target is an important anti-cancer target that is currently being focused on at home and abroad. It is believed that with the continuous deepening of the research on this target, it will play a positive role in promoting the research and application of anti-cancer drugs. The company will fully support the research of this subject, provide all-round protection in terms of talents, equipment, funds, etc., and require Dr. Zhang Qiang to spend more energy to guide and participate in project research, I look forward to the early results and the early completion of the project.
After discussion, the expert group believed that Dr. Wu Zhuo's research project was selected appropriately, based on sufficient basis, with clear objectives and requirements, and the design scheme was feasible. He himself was capable of undertaking the research of the subject, and the relevant funds and schedule were reasonable. He agreed to open the topic. (Zhu Ningyan)
More information
The company won the Taurus Award
On December 29, 2022, the "2022 High-quality Development Forum of listed companies and the 24th Golden Bull Award presentation ceremony of listed companies" jointly sponsored by China Securities News, Haikou Municipal Government and Haikou National High-tech Zone was held in Haikou. The list of Golden Bull Awards of listed companies was officially announced. With its outstanding performance, Jianfeng Group won the "2021 Golden Bull Most Investment Value Award".
2023
01-12
From December 11th to 12th, the 13th National Congress of the All-China Federation of Industry and Commerce was held in Beijing. Jiang Xiaomeng, chairman of the group company, attended the conference as a representative of Zhejiang.
2022
12-22
Yunnan Jianfeng won the title of "Harmonious Labor Relations Enterprise" in Yunnan Province
On November 18, the Yunnan Provincial Federation of Trade Unions, the Department of Human Resources and Social Security, the Entrepreneur Association and other units jointly issued a document to commend the harmonious labor relations enterprises in Yunnan Province from 2020 to 2021. Yunnan Jianfeng Cement Company is on the list and is the only enterprise in the urban area of Pu'er to receive this honor.
2022
12-13
Huang Ping Jianfeng won the title of "provincial green factory" in Guizhou
On November 30, the Guizhou Provincial Department of Industry and Information Technology released the 2022 list of green manufacturing units in Guizhou Province, and Huangping Jianfeng Cement Company was recognized as a "provincial green factory".
2022
12-13
On December 2, Yu Jianhong, general manager of the group company, gave a management lesson to the company's reserve management talents under the title of "Enterprise Management Innovation in Great Changes.
2022
12-13
On November 24, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, gave a special party lesson to all party members and cadres of the company under the title of "comprehensively promoting the Great Rejuvenation of the Chinese Nation with Chinese Modernization" to interpret and preach the spirit of the 20th CPC National Congress.
2022
12-04